View Older Stories View More Recent Stories

Sep 20, 2024 07:30AM Merck Receives Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Regimens as Treatment for Patients With Two Types of Gynecologic Cancers
Sep 18, 2024 06:46AM Merck (MRK) Announces FDA Approval of KEYTRUDA Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic MPM
Sep 18, 2024 06:45AM FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesoth
Sep 17, 2024 06:00AM Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small
Sep 16, 2024 06:16AM Merck (MRK) Reports Ten-Year Data for KEYTRUDA Demonstrated Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Sep 15, 2024 10:30AM KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk
Sep 15, 2024 08:45AM Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
Sep 14, 2024 10:35AM KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unre
Sep 14, 2024 10:30AM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Sep 14, 2024 03:15AM KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positi
Sep 11, 2024 06:45AM Merck to Participate in the Bank of America 2024 Global Healthcare Conference
Sep 11, 2024 06:30AM Merck (MRK) Reports Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL 9
Sep 11, 2024 06:30AM Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL®9 in Japanese Males
Sep 10, 2024 08:00AM MilliporeSigma Launches Single-Use Reactor Designed to Accelerate Antibody Drug Conjugate Manufacturing
Sep 7, 2024 11:30AM Ifinatamab Deruxtecan Continues to Demonstrate Promising Objective Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
Sep 4, 2024 06:45AM Merck to Present Survival Data and New Research on 10 Investigational or Approved Medicines at ESMO Congress 2024
Sep 4, 2024 06:40AM Merck (MRK) and EyeBio Initiate Phase 2b/3 Trial for Restoret
Sep 4, 2024 06:40AM Merck and EyeBio Announce Initiation of Phase 2b/3 Clinical Trial for Restoret™ for the Treatment of Diabetic Macular Edema
Sep 3, 2024 08:00AM MilliporeSigma Receives Industry First EXCiPACT Certification for Cell Culture Media Manufacturing
Sep 3, 2024 06:46AM Merck (MRK) Announces EU Approval of KEYTRUDA Plus Padcev as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
Sep 3, 2024 06:45AM European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment of Unresectable or Metastatic Urothelial Carcinoma in Adults
Aug 29, 2024 06:45AM Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Aug 29, 2024 06:30AM Merck (MRK) Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Aug 29, 2024 06:30AM Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Aug 27, 2024 06:47AM Merck (MRK) Announces Phase 3 Trial Initiation for Bomedemstat
Aug 27, 2024 06:45AM Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
Aug 26, 2024 06:47AM Merck (MRK) Receives European Commission Approval for WINREVAIR (sotatercept)
Aug 26, 2024 06:45AM Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Fu
Aug 9, 2024 06:46AM Merck (MRK) to Acquire CN201 from Curon Biopharmaceutical
Aug 9, 2024 06:45AM Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
Aug 8, 2024 06:45AM Merck (MRK) Provides Update on Phase 3 KeyVibe-008 Trial of an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab
Aug 8, 2024 06:45AM Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
Aug 6, 2024 09:00AM Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
Aug 6, 2024 06:45AM Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
Aug 1, 2024 08:01AM MilliporeSigma Announces Closing of Mirus Bio Acquisition, Bolstering Viral Vector Bioprocessing Offering
Aug 1, 2024 08:00AM IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
Jul 30, 2024 06:30AM Merck Announces Second-Quarter 2024 Financial Results
Jul 26, 2024 06:50AM Merck (MRK) Receives Positive EU CHMP Opinion for KEYTRUDA Plus Padcev as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Jul 26, 2024 06:50AM Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
Jul 23, 2024 12:52PM Merck Announces Fourth-Quarter 2024 Dividend
Jul 23, 2024 06:45AM Merck (MRK) Reports Topline Results from Phase 2b/3 Trial of Clesrovimab
Jul 23, 2024 06:45AM Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
Jul 21, 2024 06:00AM 10 policies if Trump wins and stock implications: Jefferies
Jul 16, 2024 06:45AM Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
Jul 16, 2024 05:10AM Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Jul 12, 2024 06:46AM Merck (MRK) Completes Acquisition of EyeBio
Jul 12, 2024 06:45AM Merck Completes Acquisition of EyeBio
Jul 9, 2024 08:30AM Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
Jul 1, 2024 08:15AM Merck (MRK) and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat
Jul 1, 2024 08:15AM Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Pr
View More Recent Stories View Older Stories